KYNB

MKT CAP:$29M

Kyntra Bio, Inc.

Market Cap

$29M

Healthcare·Medical - Pharmaceuticals·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$7.06-$2.10 (-22.93%)

Apr 21, 2026

Company Details

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop med...

CEO

Thane Wettig

IPO Date

Nov 14, 2014

Website

www.kyntrabio.com

Key Metrics TTM

Revenue

-$118M

-218.1% YoY

Net Income

$798.0K

EPS (Diluted)

-$0.84

Free Cash Flow

-$34M

Revenue / Share

-$29.14

Gross Margin

83.8%

Operating Margin

112.1%

Net Margin

-0.7%

FCF Margin

28.5%

P/S

—

P/E

36.3x

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 16, 2026

$6M-78.3%EPS $45.37

Q4 2025

Mar 16, 2026

$1M+101.0%EPS -$3.51

Q2 2025

Aug 11, 2025

$1M+35.1%EPS -$1.88

Q1 2025

May 12, 2025

$3M-89.2%EPS $0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$17M	$11M	-$135M
Q1 22	$61M	-$32M	-$63M
Q2 22	$30M	$23M	-$78M
Q3 22	$16M	$11M	-$94M
Q4 22	$34M	$29M	-$66M
Q1 23	$36M	$33M	-$76M
Q2 23	$44M	$39M	-$88M
Q3 23	$40M	$36M	-$63M
Q4 23	$27M	$22M	-$54M
Q1 24	$25M	-$32M	-$49M
Q2 24	$998.0K	-$32M	-$46M
Q3 24	$46M	$41M	-$17M
Q4 24	-$123M	-$103M	-$92M
Q1 25	$3M	$2M	-$15M
Q2 25	$1M	$1M	-$12M
Q4 25	$1M	$0	-$14M

Valuation

Quarter	P/S	P/E
Q4 21	146.5x	—
Q1 22	111.6x	—
Q2 22	103.5x	—
Q3 22	253.8x	—
Q4 22	334.7x	—
Q1 23	400.2x	—
Q2 23	52.7x	—
Q3 23	12.9x	—
Q4 23	13.1x	—
Q1 24	43.0x	—
Q2 24	20.7x	—
Q3 24	10.1x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q4 25	—	44.5x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$55M	-$56M
Q1 22	-$8M	-$45M
Q2 22	-$33M	-$34M
Q3 22	-$52M	-$53M
Q4 22	-$53M	-$53M
Q1 23	-$102M	-$102M
Q2 23	-$111M	-$112M
Q3 23	-$85M	-$85M
Q4 23	-$18M	-$19M
Q1 24	-$59M	-$59M
Q2 24	-$40M	-$40M
Q3 24	-$8M	-$8M
Q4 24	-$30M	-$31M
Q1 25	$3M	$3M
Q2 25	$13M	$13M
Q4 25	-$18M	-$18M

Capital Expenditures

Quarter	CapEx
Q4 21	$1M
Q1 22	$37M
Q2 22	$905.0K
Q3 22	$865.0K
Q4 22	$333.0K
Q1 23	$591.0K
Q2 23	$993.0K
Q3 23	$684.0K
Q4 23	$251.0K
Q1 24	$29.0K
Q2 24	$14.0K
Q3 24	$82.0K
Q4 24	$141.0K
Q1 25	$16.0K
Q2 25	$13.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	-74.5%	+23.4%
Q1 22	+58.3%	+13.7%
Q2 22	+22.3%	-31.7%
Q3 22	-89.9%	+4.2%
Q4 22	+107.7%	-33.8%
Q1 23	-40.6%	-9.3%
Q2 23	+48.7%	+22.5%
Q3 23	+155.1%	-5.3%
Q4 23	-21.0%	-19.1%
Q1 24	-29.9%	-33.6%
Q2 24	-97.7%	-64.2%
Q3 24	+15.4%	-39.1%
Q4 24	-554.2%	-138.9%
Q1 25	-89.2%	-76.3%
Q2 25	+35.1%	-71.7%
Q4 25	-97.2%	-76.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$17M	103.2%
Q1 22	$17M	28.2%
Q2 22	$17M	55.9%
Q3 22	$16M	98.9%
Q4 22	$16M	47.2%
Q1 23	$16M	44.6%
Q2 23	$16M	35.8%
Q3 23	$9M	23.6%
Q4 23	$9M	34.3%
Q1 24	$9M	34.5%
Q2 24	$9M	860.5%
Q3 24	$8M	16.6%
Q4 24	$178.0K	—
Q1 25	$3M	104.1%
Q2 25	$2M	138.9%
Q4 25	$1M	93.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 21	$114M	$32M
Q1 22	$89M	—
Q2 22	$71M	$30M
Q3 22	$75M	$30M
Q4 22	$62M	$34M
Q1 23	$74M	$34M
Q2 23	$95M	$31M
Q3 23	$61M	$26M
Q4 23	$52M	$24M
Q1 24	$36M	—
Q2 24	$32M	—
Q3 24	$22M	$18M
Q4 24	$1M	—
Q1 25	$9M	$8M
Q2 25	$6M	$7M
Q4 25	$7M	$7M

Revenue Segments

Quarter	Drug Product Revenue	Product
Q3 24	-$262.0K	$46M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$186M	$242M	$428M
Q2 22	$168M	$270M	$438M
Q3 22	$156M	$253M	$409M
Q4 22	$156M	$266M	$422M
Q1 23	$189M	$167M	$356M
Q2 23	$153M	$183M	$336M
Q3 23	$61M	$130M	$191M
Q4 23	$114M	$122M	$236M
Q1 24	$106M	$72M	$178M
Q2 24	$141M	$0	$141M
Q3 24	$131M	$0	$131M
Q4 24	$50M	$0	$50M
Q1 25	$34M	$0	$34M
Q2 25	$23M	$0	$23M
Q3 25	$118M	$0	$118M
Q4 25	$48M	$41M	$89M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	93M	-0.0%	+1.8%
Q1 22	93M	+0.3%	+1.5%
Q2 22	93M	+0.5%	+1.3%
Q3 22	94M	+0.3%	+1.0%
Q4 22	94M	+0.3%	+1.4%
Q1 23	95M	+0.7%	+1.8%
Q2 23	98M	+3.2%	+4.6%
Q3 23	98M	+0.5%	+4.8%
Q4 23	98M	+0.3%	+4.7%
Q1 24	99M	+0.5%	+4.5%
Q2 24	4M	-96.0%	-95.9%
Q3 24	4M	+0.7%	-95.9%
Q4 24	4M	+0.3%	-95.9%
Q1 25	101M	+2403.1%	+2.0%
Q2 25	4M	-96.0%	+1.2%
Q4 25	4M	+0.1%	+0.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$29.2K	566
Q1 22	$107.5K	566
Q2 22	$52.7K	566
Q3 22	$27.8K	566
Q4 22	$58.1K	592
Q1 23	$61.1K	592
Q2 23	$74.9K	592
Q3 23	$67.8K	592
Q4 23	$55.8K	486
Q1 24	$52.2K	486
Q2 24	$2.1K	486
Q3 24	$95.3K	486
Q4 24	-$547.8K	225
Q1 25	$12.2K	225
Q2 25	$6.0K	225
Q4 25	$6	200K

Revenue / Employee